CopyMark Law Group
4.9/5
Drawing for IMMUNOCORE

USPTO serial 87264976

IMMUNOCORE

Reviewed by CopyMark Law Group

Reg. 5410175Status 705Registered
Filing date
Status date
Registration date
Feb 27, 2018
Examiner
NUNLEY, CHRISTOPHER MICHAEL
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 705 means a Madrid-based U.S. registration has accepted Section 71 maintenance and Section 15 incontestability. The U.S. extension is active with strengthened rights. Track next renewal deadlines in TSDR and WIPO records.

Status 705: Status 705 means a Madrid-based U.S. registration has accepted Section 71 maintenance and Section 15 incontestability. The U.S. extension is active with strengthened rights.

Need help with IMMUNOCORE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Trademark Monitoring
(312) 319-4460
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Start a new application
(312) 319-4460

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Andrew D. Price & Paula E. Hopkins

Andrew D. Price & Paula E. Hopkins VENABLE LLPP.O. BOX 34385WASHINGTON, DC 20043-9998United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the treatment of cancer, infectious diseases and autoimmune diseases; biological preparations for the treatment of cancer; biological preparations for medical use for the treatment of cancer, infectious diseases and autoimmune diseases; immunotherapeutic drugs; reagents for medical use; Biological preparations for the treatment of viral infections; biological preparations for the treatment of autoimmune diseases; diagnostic preparations for medical purposes; diagnostic reagents for medical useACTIVE—
042[Pharmaceutical testing and clinical trials for others; provision of information and consultancy in relation to the aforesaid services; scientific and technological services, namely, research and design in the field of drug development for the treatment of cancer, infectious diseases and autoimmune diseases; pharmaceutical research and development services; research and development in the biotechnology field; provision of information and consultancy in relation to the aforesaid services]SECTION 8 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 30, 2024NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
Nov 30, 2024C15PREGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
Nov 30, 2024APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Nov 20, 2024ASCKASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY—
Jun 20, 2024E815TEAS SECTION 8 & 15 RECEIVED—
Feb 27, 2023REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Dec 28, 2022ASCKASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY—
Feb 27, 2018R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Dec 12, 2017NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 12, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 22, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Nov 8, 2017FIXDELECTRONIC RECORD REVIEW COMPLETE—
Nov 3, 2017ERRRON HOLD - ELECTRONIC RECORD REVIEW REQUIRED—
Oct 31, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Oct 25, 2017XAECEXAMINER'S AMENDMENT ENTERED—
Oct 25, 2017GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Oct 25, 2017GNEAEXAMINERS AMENDMENT E-MAILED—
Oct 25, 2017CNEAEXAMINERS AMENDMENT -WRITTEN—
Sep 30, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 30, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 26, 2017ALIEASSIGNED TO LIE—
Sep 19, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 22, 2017GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 22, 2017GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 22, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 14, 2017DOCKASSIGNED TO EXAMINER—
Dec 15, 2016NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Dec 15, 2016NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance